SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Britain Courts Anthropic Amid US Defense Department Dispute 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2016 -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference. Mateon’s presentation will take place on Monday, September 12, 2016 at 12:30 p.m. Eastern time in the Louis Salon at the Lotte New York Palace Hotel.
To listen to a live webcast of the presentation, please visit the Company's website, www.mateon.com. Under the "Investors & News" tab, select the link to "Events & Presentations." A replay of the webcast will be available at this same location for a period of time following the conclusion of the live event.
About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
CONTACT for investors and media: [email protected] 650-635-7000
